Clinical trial
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China…
NCT00320762 · Pro Top & Mediking Company Limited, Industry · Completed
Key facts
| NCT number | NCT00320762 |
|---|---|
| Title | Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital |
| Official title | Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery |
| Lead sponsor | Pro Top & Mediking Company Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Pterygium |
| Intervention type | Device |
| Interventions | OculusGen Biodegradable Collagen Matrix Implant |
| Enrollment | 60 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2007 |
| First posted | May 3, 2006 |
| Last update posted | May 22, 2008 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: